CRISPR Therapeutics (NASDAQ:CRSP) is predicted to double by 2030. Citizens and Bank of America recently maintained Buy ratings on the company, noting an undervalued pipeline and potential late-stage development in 2027 for up to seven opportunities. BofA highlighted factors aligning for biopharma investing and minimal drug price regulation effects.

CRISPR Therapeutics (NASDAQ:CRSP) utilizes gene editing to develop medicines for human diseases. While CRSP shows investment potential, certain AI stocks offer greater upside and less downside risk. Investors are advised to consider AI stocks that could benefit from Trump-era tariffs and the onshoring trend.

A report lists 15 African countries with the best doctors. The biotech sector has seen a return in interest due to positive data rewards, large-cap biopharma investing, private company backlog, and better capital access. Primary uncertainty lies in the longevity of this trend.

Read more at Yahoo Finance: Citizens Maintains Outperform Rating On CRISPR Therapeutics (CRSP) Citing Undervalued Pipeline